Investigation of Patients with Abnormal Response to Warfarin
Overview
Affiliations
In 55 patients in whom warfarin control had been satisfactory for at least 4 months, warfarin dose, plasma warfarin concentration and plasma clearance were measured. The mean dose to maintain the BCR (INR) between 2.3 and 3.3 was 5.1 +/- 2 mg day-1 (range 1.5-10 mg). Plasma warfarin concentrations and warfarin clearance were log-normally distributed with 95% confidence limits between 0.8 and 2.4 mg l-1 and 2.5 and 8.71 day-1 respectively. These confidence limits were used to construct algorithms which correctly predicted the cause of abnormal warfarin sensitivity in two patients and resistance in two further patients. These algorithms should help to identify the cause of abnormal warfarin responsiveness in the clinical setting.
Anticoagulant therapy in special circumstances.
DeLoughery T Curr Cardiol Rep. 2000; 2(1):74-9.
PMID: 10980876 DOI: 10.1007/s11886-000-0029-y.
Clinical utilization of the international normalized ratio (INR).
RILEY R, Rowe D, Fisher L J Clin Lab Anal. 2000; 14(3):101-14.
PMID: 10797608 PMC: 6807747. DOI: 10.1002/(sici)1098-2825(2000)14:3<101::aid-jcla4>3.0.co;2-a.
Vadher B, PATTERSON D, Leaning M Br J Clin Pharmacol. 1999; 48(1):63-70.
PMID: 10383562 PMC: 2014877. DOI: 10.1046/j.1365-2125.1999.00967.x.
Routledge P, Shetty H, White J, Collins P Br J Clin Pharmacol. 1998; 46(4):343-6.
PMID: 9803981 PMC: 1874165. DOI: 10.1046/j.1365-2125.1998.t01-1-00796.x.
Clinically important drug interactions with anticoagulants. An update.
Harder S, Thurmann P Clin Pharmacokinet. 1996; 30(6):416-44.
PMID: 8792056 DOI: 10.2165/00003088-199630060-00002.